Elevating Investor Relations for Emerging Biotech
At Ascend IR, we empower emerging biotech companies by transforming scientific breakthroughs into compelling investment stories. Our mission is to drive market visibility, build investor confidence, and create long-term value through strategic investor relations and corporate communications.
We bridge the gap between scientific innovation and financial engagement, translating groundbreaking discoveries into clear, impactful narratives that resonate with the investor community. With a proactive strategy, high-impact storytelling, and customized outreach, we guide biotech companies through public market transitions, secure vital funding, and establish a strong presence among institutional investors and analysts.
At ASCEND IR, we don’t just manage investor relations—we elevate them.
Meet Shveta Dighe
Founder, Ascend IR | Biotech Investor Relations Expert
Shveta Dighe is a seasoned biotechnology investor relations strategist with a deep understanding of the capital markets and a passion for translating scientific innovation into compelling investor narratives. With over a decade of experience in biotech investor relations and equity research, Shveta has helped emerging biotech companies navigate public markets, engage with institutional investors, and build long-term shareholder value. Read More..
Our Unique Approach
We specialize in biotech, delivering impactful storytelling and integrated communications for market success.
Tailored, High-Touch Approach
We don’t believe in one-size-fits-all strategies. Our services are customized to fit your company’s needs.
Investor-Grade Materials & Messaging
From investor decks to earnings reports, we ensure your materials meet the highest industry standards.
Deep Biotech & Capital Markets Expertise
We combine Wall Street experience with biotech know-how to drive engagement.
Proactive Strategy, Not Reactive Fixes
We anticipate challenges, shape the narrative, and position you ahead of market trends.